Molecular Vision 2008 : 14:118-124 <>
Received 2 October 2007 | Accepted 3 January 2008 | Published 24 January 2008

ABCC6 mutations in pseudoxanthoma elasticum: an update including eight novel ones

Astrid S. Plomp,1, 2 Ralph J. Florijn,1 Jacoline ten Brink,1 Bruce Castle,3 Helen Kingston,4 Ana Martín-Santiago,5 Theo G.M.F. Gorgels,1 Paulus T.V.M. de Jong,1, 6, 7 Arthur A.B. Bergen1, 2

1Department of Clinical and Molecular Ophthalmogenetics, Netherlands Institute for Neuroscience, an institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands; 2Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands; 3Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, United Kingdom; 4Regional Genetic Service, St. Mary’s Hospital, Manchester, United Kingdom; 5Department of Pediatric Dermatology, Hospital Son Dureta, Mallorca, Spain; 6Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; 7Institute of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands

Correspondence to: Professor Arthur A.B. Bergen, Ph.D., Department of Clinical and Molecular Ophthalmogenetics, Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences KNAW, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands; Phone: (31) 20 5666101; FAX: (31) 20 5666121; email:


Purpose: Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder of connective tissue, affecting the retina, the skin, and the cardiovascular system. PXE is caused by mutations in ABCC6. Up to now, the literature reports that there are 180 different ABCC6 mutations in PXE. The purpose of this paper is to report eight novel mutations in ABCC6 and to update the spectrum and frequency of ABCC6 mutations in PXE patients.

Methods: Eye, skin, and DNA examinations were performed using standard methodologies. We newly investigated the gene in 90 probands by denaturing high-performance liquid chromatography (dHPLC) and direct sequencing. We examined a total of 166 probands.

Results: Eight novel ABCC6 mutations (c.1685T>C, p.Met562Thr; c.2477T>C, p.Leu826Pro; c.2891G>C, p.Arg964Pro; c.3207C>A, p.Tyr1069X; c.3364delT, p.Ser1122fs; c.3717T>G, p.Tyr1293X; c.3871G>A, p.Ala1291Thr; c.4306_4312del, p.Thr1436fs) were found in seven unrelated patients. Currently, our mutation detection score is at least one ABCC6 mutation in 87% of patients with a clinical diagnosis of PXE.

Conclusions: Our results support that ABCC6 is the most important, and probably the only, causative gene of PXE. In total, 188 different ABCC6 mutations have now been reported in PXE in the literature.


Pseudoxanthoma elasticum (PXE; OMIM 264800) is a heritable disorder of connective tissue, affecting the skin, retina, and blood vessels. The most frequent retinal abnormalities are peau d’orange, angioid streaks, and punched-out white chorioretinal lesions, which are visible as white dots sometimes with a comet-like tail. Angioid streaks develop in almost all of the patients and often lead to choroidal neovascularization, subretinal hemorrhages, and visual loss. Skin abnormalities usually start at the lateral sides of the neck with yellowish papules that confluence into plaques. Skin of other flexural sides of the body often follows the same course, and sometimes the skin abnormalities progress to redundant folds. Patients have an increased risk of cardiovascular complications including gastro-intestinal bleedings and arteriosclerosis. The expression of the disease is variable, and substantial clinical differences exist between patients, even within families [1,2].

PXE is caused by mutations in a single gene, ABCC6 [3-5]. The inheritance is autosomal recessive. Recent clinical and molecular studies showed that putative dominant segregating PXE pedigrees are probably the result of mild expressions in heterozygous carriers or pseudodominance due to an unexpected high carrier frequency in the population [6-9].

ABCC6 belongs to the ATP-binding cassette (ABC) gene sub-family C [10,11]. ABCC6 has 31 exons spanning about 73 kb genomic DNA. The mRNA is approximately 6 kb with an open reading frame (ORF) of 4.5 kb. The ABCC6 protein consists of 1,503 amino acids and contains 17 transmembrane-spanning domains and two intracellular nucleotide binding folds (NBFs). The NBFs consist of Walker A and B domains and a C motif critical for active ATP dependent transport across the cell membrane [1,12]. The putative ABCC6 protein structure is presented in Figure 1. Two ABCC6 pseudogenes, homologous to, respectively, the first four and nine exons of ABCC6, have been identified [13,14], complicating the mutational analysis of the gene [15].

ABCC6 is highly expressed in the liver and kidney. Expression in multiple other tissues including those affected by PXE (skin, retina, and vessel walls) is low or absent. The protein was localized to the basolateral membranes of both hepatocytes in the liver and the proximal kidney tubules. The natural substrate transported by the ABCC6 protein remains to be identified. Functional studies showed that ABCC6 transports glutathione S-conjugate leukotriene C(4), S-(2,4-dinitrophenyl) glutathione, and the cyclopentapeptide BQ123 [16-18]. The present view is that ABCC6 transports substrates from the liver and kidney cells back into the blood [10,18].

Up to now, 180 different mutations in ABCC6 have been reported (Appendix 1). Mutations were found throughout the gene, but there is a high concentration in and around the NBFs and in the eighth cytoplasmatic loop [7,9,12,19-21]. Mutation detection rates varied from 55%-97% among the different studies.

The purpose of this paper was to report eight novel mutations in ABCC6 and to update the mutation spectrum and frequency of ABCC6 mutations in PXE patients.


DNA of all probands/families (n=166) was collected by one of us or sent to the Netherlands Institute for Neuroscience, a referral center for geneticists and ophthalmologists from the Netherlands and other European countries, for mutational analysis of ABCC6. The patients, who had novel mutations, were clinically examined by one of us (A.P., B.C., H.K., A.M., P.dJ.) except for cases 4 and 7, and data from dermatologic, ophthalmic, and cardiovascular examinations elsewhere were collected. The dermatologic examination consisted of an inspection of the skin and histopathology of a skin biopsy. The ophthalmic examination included an assessment of visual acuity, slit-lamp examination of the anterior segment, biomicroscopy with a 90 diopter lens of the posterior pole of the eye fundus, indirect ophthalmoscopy of the peripheral retina, and digital photography of as many of the fundus signs as feasible. The cardiovascular examination included at least measurement of blood pressure, electrocardiography, and echocardiography. The clinical diagnosis of PXE was considered definite if at least two of the three following criteria were met: characteristic skin lesions at the lateral side of the neck and/or other flexural regions of the body, fragmentation and calcification of elastic fibers in a skin biopsy, and characteristic retinal lesions (peau d’orange, angioid streaks, and/or punched-out white chorioretinal lesions).

DNA was isolated from peripheral blood by standard techniques. Polymerase chain reaction (PCR) primers, amplification conditions, and mutation analysis strategy were essentially performed as described previously [22]. After pre-screening for common mutations, all coding exons were screened by denaturing high-performance liquid chromatography (dHPLC). Exonic fragments with changed dHPLC patterns were further analyzed by direct sequencing. The known deletions of exons 23–29 and exon 15 were analyzed as described [22].

The nomenclature for mutations was based on previously published recommendations [23] and additional guidelines. The ABCC6 cDNA consensus sequence (GenBank AF076622) was used for DNA mutation description.

When a novel mutation was found, at least 140 control chromosomes were screened for this mutation. The controls were Caucasian individuals without any eye disease or any other apparent disorder. When the mutation was a missense mutation, conservation of the changed amino acid was checked by ClustalW multiple sequence alignment comparison for ABCC6 or other closely related proteins in Felis catus, Gallus gallus, Monodelphis domestica, Mus musculus, Ornythorhynchus anatinus, Otolemur garnetii, Pan troglodytes, and Rattus norvegicus. An amino acid was considered to be conserved when it was present in multiple proteins in these animals.


We found eight novel ABCC6 mutations (c.1685T>C, c.2477T>C, c.2891G>C, c.3207C>A, c.3364delT, c.3717T>G, c.3871G>A, and c.4306_4312del). None of these mutations were present in the control chromosomes. The eight novel mutations were found in seven patients in whom the clinical diagnosis of PXE was unambiguously established. All had characteristic skin abnormalities (Figure 2) either confirmed by a skin biopsy or in combination with characteristic ophthalmologic signs or by both (Table 1). Below, we present the molecular data in detail together with family data where relevant.

In case 1, analysis of ABCC6 revealed two mutations, the earlier reported c.3662G>A (p.Arg1221His) [24] and the novel mutation c.1685T>C (Met562Thr). This latter missense mutation changes a well conserved amino acid at the fifth extracellular loop of the protein.

In case 2, we found the previously reported pathogenic sequence change, c.2787+1G>T, in intron 21 of ABCC6 [25,26] and the novel mutation, c.2477T>C (p.Leu826Pro), in exon 19. This missense mutation is located just after NBF1 and leads to the change of a well conserved amino acid.

In case 3, one missense mutation was found in ABCC6, the novel mutation c.2891G>C (p.Arg964Pro), which leads to the change of a well conserved amino acid between NBF1 and NBF2. No second mutation was found.

In case 4, we found a c.3207 C>A (p.Tyr1069X) nonsense mutation as well as a c.3871G>A (p.Ala1291Thr) missense mutation in ABCC6. Both mutations have not been reported before. The former mutation theoretically results in a premature chain termination and an absent or dysfunctional protein. The latter mutation changes a well conserved amino acid in NBF2.

In case 5, two mutations were found in ABCC6, the well-known deletion of exon 23–29 and the novel mutation, c.3364delT. The angioid streaks and peau d’orange of the retina of her right eye can be observed in Figure 3. She had minimal skin abnormalities at the lateral side of her neck, just below the hair line, which were not noticed before. Her father also had a clinical diagnosis of PXE. He had peau d’orange of the retina, angioid streaks, and macular degeneration after subretinal neovascularization in both eyes. The dermatologist did not find characteristic skin lesions, but a skin biopsy from the left side of the neck showed clumping and calcification of elastic fibers. He had the exon 23–29 deletion. The mother of case 5 had the c.3364delT mutation. We did not find a second mutation in the father.

Case 6 was homozygous for a novel mutation in ABCC6, c.3717T>G leading to a stop codon at position 1239 of the protein (p.Tyr1239X) just before NBF2. The patient’s sister was said to be affected as well. Consanguinity between the parents was denied.

Mutational analysis of ABCC6 in case 7 revealed the earlier reported mutation, c.4015C>T (p.Arg1339Cys) [25], and the novel mutation, c.4306_4312del. This new mutation theoretically leads to a frameshift and the introduction of a stop codon at position 1461 of the protein.

In our entire data set, we found two causative ABCC6 mutations in 76 of 166 (46%) PXE probands and only a single mutation in 51 (31%) probands. In 39 (23%) probands, we did not find any mutation. PXE had been diagnosed in 19 of these patients. In the remaining 20 patients, there was either doubt about the diagnosis or not enough clinical data to prove the diagnosis. Thus at least one mutation was found in 127 (87%) of 146 probands in whom the clinical diagnosis was established a priori. This means that we found mutations in 203 (69.5%) out of 292 alleles. The type and frequencies of the different mutations found are listed in Appendix 1. Part of the patient and mutation data described here was published previously [19,22].


In this study, eight novel mutations were found, which we consider to be implicated in PXE: c.1685T>C (p.Met562Thr), c.2477T>C (p.Leu826Pro), c.2891G>C (p.Arg964Pro), c.3207C>A (p.Tyr1069X), c.3364delT (p.Ser1122fs), c.3717T>G (p.Tyr1293X), c.3871G>A (p.Ala1291Thr), and c.4306_4312del (p.Thr1436fs). All of these mutations were not present in at least 140 control chromosomes, and the missense mutations lead to the change of a well conserved amino acid. This suggests that these mutations are pathogenic. Four novel mutations target the eighth cytoplasmatic loop (c.3364delT) or NBF2 (c.3717T>G, c.3871G>A, and c.4306_4312del). Both domains are known hot spots for ABCC6 mutations. Three other new mutations (c.2477T>C, c.3207C>A, and c.2891G>C) are located in between NBF1 and NBF2. The c.2477T>C mutation occurs just after NBF1 in an area targeted by three previously described mutations (c.2420G>A, c.2428G>A, and c.2458G>C). The c.3207C>A and c.2891G>C mutations target less frequently mutated domains of the ABCC6 protein. The last novel mutation, c.1685T>C, is uniquely located at the fifth extracellular loop before NBF1.

In our entire data set, at least one ABCC6 mutation was identified in 127 (77%) of 166 probands in which there were clinical suspicions of PXE. If we exclude the 20 patients whose clinical diagnoses were questionable, we find at least one mutation in 87% of probands. We found 40 different mutations of which c.3421C>T (p.Arg1141X), c.3775delT, and a deletion of exons 23-29 were most frequent. The p.Arg1141X mutation was found in 33% of alleles with a mutation, and the latter two mutations were found in 14% and 13% of the alleles, respectively.

We did not find any mutation in 19 of the 146 (13%) probands with a clinical diagnosis of PXE. In 51 of 146 (35%) probands, we only found one mutation. As inheritance is autosomal recessive, it is to be expected that these probands have two mutations. Taken together, our missing rate per allele is 35%, which suggests that a considerable part of the mutations in our data set could not be identified.

Four studies in which the patients had clinically definite PXE diagnoses reported missing rates of 3% [7] or 17.1% [27] after sequencing and 12.3% [20], 14% [28], or 34% [21] after denaturing high-performance liquid chromatography (dHPLC). It is largely unclear why mutation detection rates are different in several studies. What are the possible explanations?

Geographic differences in patient populations

Most of the patients in the above mentioned studies were from Italy [27], Germany [20], France [28], and the United States [7,21]. Most of our patients were from the Netherlands. Mutation frequencies differ in different populations [12]. It is conceivable that a relatively frequent mutation in certain populations can be missed by the techniques used. Heterozygous deletions of (or part of) the gene and mutations in the promoter region and in introns can easily be missed. Thirteen French PXE patients with at least one unidentified mutation (18 unidentified alleles) after dHPLC were studied with a quantitative multiplex PCR of short fluorescent fragments (QMPSF) [28]. Five (novel) deletions were detected. This reduced the total missing rate from 14% to 10% of 130 alleles. Deletions can also be detected with multiplex ligation-dependent probe amplification (MLPA), but both QMPSF and MLPA are not yet routinely used.


Sequencing the gene will yield additional missense mutations, which are missed by dHPLC. This could at least partly explain the high detection rate of Miksch et al. [7].

Differences in patient selection

We did not have detailed clinical information of all patients and, as a result, there were some patients without a definite diagnosis of PXE. Some patients could have a PXE-like phenotype as can be seen in beta-thalassemia, sickle cell anemia, and peri-umbilical perforating PXE [1].

Digenic inheritance

Another, less likely, possibility is digenic inheritance in the patients without two mutations. The combination of one ABCC6 mutation with a mutation in another gene could lead to PXE. This could be different for different populations.

Including the mutations presented here, at least 188 different ABCC6 mutations have been published to date in the international literature (Appendix 1). In the European populations, the p.Arg1141X mutation is by far the most prevalent (about 28% of alleles) while in the United States population, the exon 23–29 deletion occurs most frequently (also about 28% of alleles) [25,29]. The mutation distribution in ABCC6 (Figure 1) shows three mutation hot spot domains: the first and second NBF as well as the eighth cytoplasmatic loop. Indeed, the latter is truly a hot spot for mutations since the frequent mutations, p.Arg1141X and the exon 23–29 deletion, target this area. It has been suggested that the eighth cytoplasmatic loop may be involved in ABCC6 substrate recognition [12]. In our data set, mutations in these three domains were found in 71% of the alleles with mutations. Screening of the involved exons 16–18, 24, and 27–30 together with the detection of the exon 23–29 deletion would detect 95% of all of our mutations.

In all of our patients who had novel mutations, a diagnosis of PXE could be made clinically (Table 1). The group was too small to establish genotype-phenotype correlations. In the data set, we observed considerable intra-and interfamilial variations in phenotype, and we could not extract a genotype-phenotype relationship either. Previous reports on potential genotype-phenotype correlations revealed variable results. Diagnosis at a significantly younger age and a higher number of affected organs were found in the case of mutations that lead to an absence of (functional) MRP6 [30]. It was suggested that nonsense mutations were more frequently associated with generalized involvement [27]. However, even in an extended patient series, no clear genotype-phenotype correlation could be found to date [7,19,21,25,27]. Besides, there is marked variable expression within family members with the same genotype [19,27,31].

In summary, we provide further evidence that ABCC6 is the most important, and probably the only, causative gene implicated in PXE. We added eight new mutations to the ABCC6 mutation spectrum and supported the notion that most mutations are present in the cytoplasmatic domains at the carboxy terminal end of the protein, especially in the three putative important functional domains of ABCC6 (NBF1, NBF2, and the eighth cytoplasmatic loop).

Appendix 1. All ABCC6 mutations which are implicated in pseudoxanthoma elasticum


The authors thank the Algemene Nederlandse Vereniging ter Voorkoming van Blindheid for support of our Ophthalmogenetic research program.


  1. Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv Ophthalmol. 2003; 48:424-38. [PMID: 12850230]
  2. Neldner KH. Pseudoxanthoma elasticum. Clin Dermatol. 1988; 6:1-159. [PMID: 3359381]
  3. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, Swart J, Kool M, van Soest S, Baas F, ten Brink JB, de Jong PT. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet. 2000; 25:228-31. [PMID: 10835643]
  4. Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, Pasquali-Ronchetti I, Pope FM, Richards A, Terry S, Bercovitch L, De Paepe A, Boyd CD. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet. 2000; 25:223-7. [PMID: 10835642]
  5. Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA. 2000; 97:6001-6. [PMID: 10811882]
  6. Bergen AA. Pseudoxanthoma elasticum: the end of the autosomal dominant segregation myth. J Invest Dermatol. 2006; 126:704-5. [PMID: 16541094]
  7. Miksch S, Lumsden A, Guenther UP, Foernzler D, Christen-Zach S, Daugherty C, Ramesar RK, Lebwohl M, Hohl D, Neldner KH, Lindpaintner K, Richards RI, Struk B. Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutations in ABCC6. Hum Mutat. 2005; 26:235-48. [PMID: 16086317]
  8. Plomp AS, Hu X, de Jong PT, Bergen AA. Does autosomal dominant pseudoxanthoma elasticum exist? Am J Med Genet A. 2004; 126:403-12. [PMID: 15098239]
  9. Ringpfeil F, McGuigan K, Fuchsel L, Kozic H, Larralde M, Lebwohl M, Uitto J. Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity. J Invest Dermatol. 2006; 126:782-6. [PMID: 16410789]
  10. Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999; 59:175-82. [PMID: 9892204]
  11. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537-92. [PMID: 12045106]
  12. Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet. 2005; 42:881-92. [PMID: 15894595]
  13. Cai L, Lumsden A, Guenther UP, Neldner SA, Zach S, Knoblauch H, Ramesar R, Hohl D, Callen DF, Neldner KH, Lindpaintner K, Richards RI, Struk B. A novel Q378X mutation exists in the transmembrane transporter protein ABCC6 and its pseudogene: implications for mutation analysis in pseudoxanthoma elasticum. J Mol Med. 2001; 79:536-46. [PMID: 11692167]
  14. Germain DP. Pseudoxanthoma elasticum: evidence for the existence of a pseudogene highly homologous to the ABCC6 gene. J Med Genet. 2001; 38:457-61. [PMID: 11474653]
  15. Pulkkinen L, Nakano A, Ringpfeil F, Uitto J. Identification of ABCC6 pseudogenes on human chromosome 16p: implications for mutation detection in pseudoxanthoma elasticum. Hum Genet. 2001; 109:356-65. [PMID: 11702217]
  16. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002; 62:6172-7. [PMID: 12414644]
  17. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002; 277:16860-7. [PMID: 11880368]
  18. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000; 57:634-41. [PMID: 10692506]
  19. Hu X, Plomp A, Wijnholds J, ten Brink J, van Soest S, van den Born LI, Leys A, Peek R, de Jong PT, Bergen AA. ABCC6/MRP6 mutations: further insight into the molecular pathology of pseudoxanthoma elasticum. Eur J Hum Genet. 2003; 11:215-24. [PMID: 12673275]
  20. Schulz V, Hendig D, Henjakovic M, Szliska C, Kleesiek K, Gotting C. Mutational analysis of the ABCC6 gene and the proximal ABCC6 gene promoter in German patients with pseudoxanthoma elasticum (PXE). Hum Mutat. 2006; 27:831 [PMID: 16835894]
  21. Pfendner EG, Vanakker OM, Terry SF, Vourthis S, McAndrew PE, McClain MR, Fratta S, Marais AS, Hariri S, Coucke PJ, Ramsay M, Viljoen D, Terry PF, De Paepe A, Uitto J, Bercovitch LG. Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum. J Med Genet. 2007; 44:621-8. [PMID: 17617515]
  22. Hu X, Plomp A, Gorgels T, Brink JT, Loves W, Mannens M, de Jong PT, Bergen AA. Efficient molecular diagnostic strategy for ABCC6 in pseudoxanthoma elasticum. Genet Test. 2004; 8:292-300. [PMID: 15727254]
  23. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000; 15:7-12. [PMID: 10612815]
  24. Kiec-Wilk B, Surdacki A, Dembinska-Kiec A, Michalowska J, Stachura-Deren M, Dubiel JS, Dudek D, Rakowski T, Szastak G, Bodzioch M, Aslanidis C, Schmitz G. Acute myocardial infarction and a new ABCC6 mutation in a 16-year-old boy with pseudoxanthoma elasticum. Int J Cardiol. 2007; 116:261-2. [PMID: 16854481]
  25. Le Saux O, Beck K, Sachsinger C, Silvestri C, Treiber C, Goring HH, Johnson EW, De Paepe A, Pope FM, Pasquali-Ronchetti I, Bercovitch L, Marais AS, Viljoen DL, Terry SF, Boyd CD. A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum. Am J Hum Genet. 2001; 69:749-64. [PMID: 11536079]
  26. Uitto J, Pulkkinen L, Ringpfeil F. Molecular genetics of pseudoxanthoma elasticum: a metabolic disorder at the environment-genome interface? Trends Mol Med. 2001; 7:13-7. [PMID: 11427982]
  27. Gheduzzi D, Guidetti R, Anzivino C, Tarugi P, Di Leo E, Quaglino D, Ronchetti IP. ABCC6 mutations in Italian families affected by pseudoxanthoma elasticum (PXE). Hum Mutat. 2004; 24:438-9. [PMID: 15459974]
  28. Chassaing N, Martin L, Bourthoumieu S, Calvas P, Hovnanian A. Contribution of ABCC6 genomic rearrangements to the diagnosis of pseudoxanthoma elasticum in French patients. Hum Mutat. 2007; 28:1046 [PMID: 17823974]
  29. Hu X, Peek R, Plomp A, ten Brink J, Scheffer G, van Soest S, Leys A, de Jong PT, Bergen AA. Analysis of the frequent R1141X mutation in the ABCC6 gene in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 2003; 44:1824-9. [PMID: 12714611]
  30. Schulz V, Hendig D, Szliska C, Gotting C, Kleesiek K. Novel mutations in the ABCC6 gene of German patients with pseudoxanthoma elasticum. Hum Biol. 2005; 77:367-84. [PMID: 16392638]
  31. Chassaing N, Martin L, Mazereeuw J, Barrie L, Nizard S, Bonafe JL, Calvas P, Hovnanian A. Novel ABCC6 mutations in pseudoxanthoma elasticum. J Invest Dermatol. 2004; 122:608-13. [PMID: 15086542]